Chris Austin and NCATS aims towards drug development to cure rare diseases

0
114

Francis Collins, Director of NIH, proposed to improve the existing drugs to speed up the treatments in the clinics. National Centre for Advancing Translational Sciences (NCATS) extends its helping hand to provide new tools to make it possible.

Chris Austin took charge of the new translational science center in 2012, and after seven years he believes that drug development will eventually help in better treatments. Austin says that other NIH industries are focusing upon particular diseases, whereas he wishes to cure the system by giving in better remedies.

Austin is pushing the efforts to improve the therapeutics development efforts to improve the bioinformatics across the centers. The Clinical and Translational Science Awards (CTSA) are reviewing different institutions by using a separate review board. They mention that NCATS is contributing its immense efforts to support the plan of drug development.

NCATS has proposed more than 40 drug development efforts as a cure to major rare diseases that are clinically approved. Austin is taking inspiration and eyeing towards removing the roadblocks and move forward with the drug development mission. Austin is eyeing towards developing and improving the efficacy and toxicity of the drugs, tissue chips, pluripotent stem cells, and 3D bio-printed organs.

The drug companies do not widely accept these tools but the industries are usually slow to accept new technologies. Austin keeps up the hope that the program initiated by him and NCATS will pay off in the long run.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here